Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-5401, INO-9012, and Cemiplimab in Newly-Diagnosed Glioblastoma
NCT03491683Phase 2Active, not recruiting
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- May 2018
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of INO-5401, ino-9012 in glioblastoma (GBM), sponsored by Inovio Pharmaceuticals, Inc.. Started May 2018; status: active, not recruiting.
02
Drugs
INO-5401ino-9012
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03491683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491683.